The current status of irinotecan (CPT-11) in the United States

被引：17

作者：

Rothenberg, ML

机构：

来源：

CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT | 1996年 / 803卷

关键词：

D O I：

10.1111/j.1749-6632.1996.tb26397.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：272 / 281

页数：10

相关论文

共 18 条

[1] PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
ABIGERGES, D
CHABOT, GG
ARMAND, JP
HERAIT, P
GOUYETTE, A
GANDIA, D
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 210 - 221
[2] ABIGERGES D, 1993, P AN M AM SOC CLIN, V12, P133
[3] Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
Conti, JA
Kemeny, NE
Saltz, LB
Huang, Y
Tong, WP
Chou, TC
Sun, M
Pulliam, S
Gonzalez, C
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 709 - 715
[4] DRENGLER R, 1996, P AN M AM SOC CLIN, V15, P489
[5] GUPTA E, 1994, CANCER RES, V54, P3723
[6] KAVANAGH JJ, 1996, P AN M AM SOC CLIN, V15, P281
[7] LESTINGI TM, 1995, P AN M AM SOC CLIN, V14, P480
[8] PITOT HC, 1996, P AN M AM SOC CLIN, V15, P494
[9] PITOT HC, 1994, P AM SOC CLIN ONCOL, V13, P197
[10] POTKUL RK, 1995, P AM SOC CLIN ONCOL, V14, P279